Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Major Depressive Disorder · Migraine · AXSM

Axsome Therapeutics

Axsome Therapeutics clinical programs — 18 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
One World Trade Center, New York, NY 10007, US HQ
2012 Founded
981 Employees
Public company Type
AXSM · NYSE Ticker
Company details
Status
Public
HQ
One World Trade Center, New York, NY 10007, US
Founded
2012
Employees
981
Programs
28
Drugs
12
Patents
162
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Axsome Therapeutics projects

18 ClinicalTrials.gov programs sponsored by Axsome Therapeutics.

Axsome Therapeutics has 18 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

18 programs

Clinical programs

  1. AXS-02

    Axsome Therapeutics

    Osteoarthritis, Knee

    phase 3 small molecule active

    1 trial

  2. AXS-02 (oral zoledronate)

    Axsome Therapeutics

    Complex Regional Pain Syndrome

    phase 3 small molecule active

    1 trial

  3. AXS-05

    Axsome Therapeutics

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    3 trials

  4. AXS-05

    Axsome Therapeutics

    Treatment Resistant Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  5. AXS-05

    Axsome Therapeutics

    Depression

    phase 3 small molecule completed

    1 trial

  6. AXS-05 (dextromethorphan and bupropion) oral tablets

    Axsome Therapeutics

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  7. AXS-05 (dextromethorphan-bupropion)

    Axsome Therapeutics

    Agitation in Patients With Dementia of the Alzheimer's Type

    phase 3 small molecule completed

    2 trials

  8. AXS-07

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    1 trial

  9. AXS-07 (MoSEIC meloxicam and rizatriptan)

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    2 trials

  10. AXS-07 (meloxicam-rizatriptan)

    Axsome Therapeutics

    Migraine

    phase 3 small molecule completed

    1 trial

  11. AXS-12 (Reboxetine)

    Axsome Therapeutics

    Narcolepsy

    phase 3 small molecule completed

    3 trials

  12. AXS-14 (Esreboxetine)

    Axsome Therapeutics

    Fibromyalgia

    phase 3 small molecule active

    1 trial

  13. SOL-BED-303

    Axsome Therapeutics

    Binge-Eating Disorder

    phase 3 small molecule active

    1 trial

  14. Solriamfetol 150 MG

    Axsome Therapeutics

    Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

    phase 3 small molecule active

    1 trial

  15. Solriamfetol 150 mg

    Axsome Therapeutics

    Binge-Eating Disorder

    phase 3 small molecule active

    1 trial

  16. Solriamfetol 150 mg

    Axsome Therapeutics

    Excessive Sleepiness

    phase 3 small molecule active

    1 trial

  17. Solriamfetol 150 mg

    Axsome Therapeutics

    ADHD

    phase 3 small molecule completed

    1 trial

  18. Solriamfetol 300 mg

    Axsome Therapeutics

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Axsome Therapeutics have?

18 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.